Given that LSD1 is a potential therapeutic target for cancer, many targeted inhibitors of LSD1 with excellent anticancer activity have been reported, and some of these inhibitors have entered clinical trials (Maes et al., 2018; Wimalasena et al., 2020; Fang et al., 2021; Yang et al., 2022). Here, KDM1A is linked to cancer.